Bekanntmachung • 14h
COMPASS Pathways plc to Report Q1, 2026 Results on May 13, 2026 COMPASS Pathways plc announced that they will report Q1, 2026 results Pre-Market on May 13, 2026 Bekanntmachung • Apr 27
Compass Pathways Plc Announces FDA Grants NDA Rolling Review Request And Awards Commissioner's National Priority Voucher Compass Pathways plc announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. Compass has generated positive data from two large, well controlled Phase 3 clinical trials. Based on the strength of the data, the FDA granted a rolling NDA submission and review. COMP360 is the first classic psychedelic to consistently achieve a highly statistically significant result and clinically meaningful effect in two phase 3 studies, with a generally well-tolerated and safe profile. With data generated across more than 1,000 participants living with TRD, COMP360’s clinical profile is redefining rapidity and durability for TRD patients. COMP360 may demonstrate effects as quickly as within one day after administration with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses. With respect to COMP360’s safety profile, a significant majority of treatment-emergent adverse events (TEAEs) are mild or moderate in severity, and the vast majority resolve within 24 hours. Depression, one of the most common mental health disorders, significantly impacts relationships, work performance, overall quality of life, and is associated with an increased risk of suicide. Major depressive disorder has been ranked as the third cause of the burden of disease worldwide in 2008 by the World Health Organization (WHO), which has projected that this disease will rank first by 2030. It is estimated that approximately 4 million patients in the U.S. with MDD live with TRD. TRD is broadly defined as an inadequate response to two or more appropriate courses of approved medications. TRD has a significantly greater impact on individuals compared to MDD, leading to residual symptoms, poorer quality of life, increased comorbidities, higher mortality, and an increased risk of suicide compared to non-treatment resistant MDD. COMP360 has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Bekanntmachung • Apr 20
Compass Pathways plc Reports Positive Phase 3 Trials and Regulatory Progress for Comp360 Synthetic Psilocybin Treatment Compass Pathways plc welcomed the White House Executive Order on accelerating medical treatments for serious mental illness. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. Compass has recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that demonstrates effects within one day and durability lasting at least through 6 months after just one or two doses for those who have a clinically meaningful response, as well as a generally well-tolerated and safe profile. Compass is already actively working with the FDA on a rolling submission and review for COMP360 in TRD. An estimated four million Americans are living with TRD and 13 million with PTSD - two conditions that have seen critically limited innovation for decades and where Compass has late-stage clinical programs underway, as well as ongoing work with the VA. With the Executive Order including the potential for accelerated regulatory and rescheduling processes, should COMP360 be approved, Compass will be ready to make this treatment available to patients. COMP360 is the first classic psychedelic to consistently achieve a highly statistically significant result and clinically meaningful effect in two phase 3 studies, with a generally well-tolerated and safe profile. With data generated across more than 1,000 participants living with treatment-resistant depression, COMP360’s transformative clinical profile is redefining rapidity and durability for TRD patients. Unlike any other approved treatment available for this patient population, COMP360 may demonstrate effects as quickly as within one day with durability lasting at least through 6 months, after only one or two doses, for those who achieve a clinically meaningful response. With respect to COMP360’s safety profile, a significant majority of treatment-emergent adverse events (TEAEs) are mild or moderate in severity, and the vast majority resolve within 24 hours. Based on this data, Compass is actively working with the FDA on a rolling submission and review for COMP360 in TRD. Compass also continues to chart the path forward for patients living with PTSD. After receiving clearance for their IND in this indication, Compass is starting a late-stage trial. Bekanntmachung • Apr 16
COMPASS Pathways plc, Annual General Meeting, May 27, 2026 COMPASS Pathways plc, Annual General Meeting, May 27, 2026. Location: goodwin procter (uk) llp, sancroft, 10-15 newgate st, london ec1a 7az, United Kingdom New Risk • Mar 26
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$53m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$53m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$47m net loss in 3 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). New Risk • Feb 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$151m net loss in 3 years). Shareholders have been diluted in the past year (23% increase in shares outstanding). Bekanntmachung • Feb 19
COMPASS Pathways plc has completed a Follow-on Equity Offering in the amount of $149.999875 million. COMPASS Pathways plc has completed a Follow-on Equity Offering in the amount of $149.999875 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 17,500,000
Price\Range: $8
Discount Per Security: $0.48
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 1,250,000
Price\Range: $7.9999
Discount Per Security: $0.48 Bekanntmachung • Jan 07
Compass Pathways plc Announces FDA Acceptance of Ind Application for PTSD Compass Pathways plc announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar to discuss the company's clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. Bekanntmachung • Oct 30
Compass Pathways plc Appoints Jeffrey Jonas to Board of Directors, Effective October 29, 2025 Compass Pathways plc announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective October 29, 2025. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on neuroscience. As part of this Board transition, Thomas Lönngren will retire from his position on the Board at the end of December after more than six years of service. Mr. Lönngren has been an invaluable counselor across the company’s achievements, including the advancement of the COMP360 program and transition from an early-stage to late-stage clinical company. Dr. Jonas is a partner at Cure Ventures, a life sciences venture capital firm focused on advancing transformative therapeutics. Dr. Jonas has held executive leadership roles across various life science organizations. At Sage Therapeutics, Dr. Jonas served as Chief Executive Officer from 2013-2020, and subsequently as Chief Innovation Officer from 2020-2022 and was a member of the Board from 2013-2024. Earlier in his career, he was President of the Regenerative Medicine Division at Shire Pharmaceuticals, guiding strategic direction and driving key R&D milestones. He also held senior roles at ISIS Pharmaceuticals, Forest Laboratories, and Upjohn Laboratories. Dr. Jonas currently serves on the Board of Directors of Generation Bio Co. (Nasdaq: GBIO), and chairs the Board of Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders. Previously, Dr. Jonas served on the board of directors of Karuna Therapeutics Inc. He has an extensive record of over 40 years of peer-reviewed scientific publications focused on psychiatric disorders, pharmacotherapy and neuropsychopharmacology. Dr. Jonas earned his B.A. from Amherst College and his M.D. from Harvard Medical School. He completed his psychiatry residency at Harvard, where he also served as Chief Resident of Psychopharmacology at McLean Hospital. Bekanntmachung • Oct 28
COMPASS Pathways plc to Report Q3, 2025 Results on Nov 04, 2025 COMPASS Pathways plc announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025 Bekanntmachung • Sep 02
Compass Pathways plc Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder Compass Pathways plc announced the publication of results from an open-label Phase 2 study evaluating the safety and tolerability of a single-dose of 25 mg of investigational COMP360 synthetic psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The Phase 2 study findings, previously disclosed in May 2024, show that COMP360 was well tolerated and indicated both rapid and durable improvement in symptoms from baseline observed out to 12 weeks following a single administration. The international Phase 2 study was conducted across three sites in the U.K. and the U.S. The study findings were published in the Journal of Psychopharmacology. There are currently only two FDA-approved medications for PTSD. The company are pioneering the development of a new model of psilocybin treatment, in which proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Bekanntmachung • Jul 29
Compass Pathways plc Announces Board Changes Compass Pathways plc announced the appointment of Justin Gover to its Board of Directors, effective immediately. Mr. Gover brings more than 25 years of leadership in the biopharmaceutical industry to this role. As part of this Board transition, Dr. Linda McGoldrick will retire from her position on the Board at the end of October after more than 5 years of service. Having helped guide Compass’s growth through its 2020 initial public offering and early clinical milestones, Dr. McGoldrick has been a key and invaluable counselor in the company’s achievements. As the founding Chief Executive Officer of GW Pharmaceuticals plc, Mr. Gover led the company from its inception in 1999 through its $7 billion acquisition by Jazz Pharmaceuticals in 2021. During his tenure, GW achieved multiple industry milestones, including the FDA approval of Epidiolex, the first plant derived cannabinoid medicine, and built a fully integrated global organization spanning R&D, manufacturing, and commercial operations. Mr. Gover currently serves on the board of Xenon Pharmaceuticals and is actively involved with nonprofit organizations including the Rady Children’s Hospital Institute for Genomic Medicine and CURE Epilepsy. Bekanntmachung • Jul 22
COMPASS Pathways plc to Report Q2, 2025 Results on Jul 31, 2025 COMPASS Pathways plc announced that they will report Q2, 2025 results on Jul 31, 2025 Bekanntmachung • Jun 23
Compass Pathways plc Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Compass Pathways plc announced the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint is the difference in change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6. A single dose of COMP360 25 mg versus placebo demonstrated a highly statistically significant reduction in symptom severity with a p-value of The ongoing Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic to report Phase 3 efficacy data. This randomized, double-blind, placebo-controlled study, which dosed 258 participants with TRD across 32 sites in the United States, aims to assess the efficacy and safety of a single dose of Company360 25 mg versus placebo for reducing symptom severity in TRD. Bekanntmachung • May 08
COMPASS Pathways plc has filed a Follow-on Equity Offering in the amount of $150 million. COMPASS Pathways plc has filed a Follow-on Equity Offering in the amount of $150 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Transaction Features: At the Market Offering Bekanntmachung • Apr 28
COMPASS Pathways plc to Report Q1, 2025 Results on May 08, 2025 COMPASS Pathways plc announced that they will report Q1, 2025 results on May 08, 2025 Bekanntmachung • Apr 22
Compass Pathways plc Announces Dosing Complete for All Participants in Part A of Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression Compass Pathways plc announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. Bekanntmachung • Apr 18
COMPASS Pathways plc, Annual General Meeting, Jun 12, 2025 COMPASS Pathways plc, Annual General Meeting, Jun 12, 2025. Location: goodwin procter (uk) llp, sancroft, 10-15 newgate st, london ec1a 7az., United Kingdom Bekanntmachung • Mar 26
Compass Pathways plc Announces Completion of Recruitment for the Phase 3 COMP360 Psilocybin for Treatment-Resistant Depression Compass Pathways plc announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depressant medications, if necessary, and those eligible will receive a dose of either 25 mg of COMP360 or placebo. Up to a third of people with depression are failed by multiple attempts at treatment. The pivotal phase 3 clinical program of COMP360 psilocybin treatment in TRD is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Top-line 6-week (primary endpoint) COMP005 data is expected late in the second quarter 2025 and 26-week COMP005 data is expected once all participants in the COMP006 trial have completed part A of the COMP006 trial. The company are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of investigational COMP360 psilocy bin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Bekanntmachung • Mar 18
Compass Pathways plc Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression Compass Pathways plc announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg COMP360 psilocybin demonstrated a longer maintenance of antidepressant effects compared to the 1 mg and 10 mg doses. Bekanntmachung • Feb 18
COMPASS Pathways plc to Report Q4, 2024 Results on Feb 27, 2025 COMPASS Pathways plc announced that they will report Q4, 2024 results on Feb 27, 2025 Bekanntmachung • Jan 21
Compass Pathways plc Appoints Steve Levine, M.D., as Chief Patient Officer Compass Pathways plc announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by the company are focused on addressing unmet needs in current clinical care and are designed to improve patient outcomes. Dr. Levine has been a member of the Compass team since 2020, serving as Senior Vice President of Patient Access. Dr. Levine is a board-certified psychiatrist who has spent his career working across multiple facets of the healthcare system to improve people’s lives through creating access to innovation. Dr. Levine completed his internship and residency in psychiatry at New York - Presbyterian Hospital/Weill Cornell Medical Center. He then completed a fellowship subspecialty training in psychosomatic medicine/psycho-oncology at Memorial Sloan Kettering Cancer Center/New York - Presbyterian Hospital. Prior to Compass, he led the company he founded in 2010, Actify Neurotherapies, that built new models of care delivery across the US for interventional psychiatry treatments. He has published extensively in both peer-reviewed journals and popular media, presented to both professional and lay audiences around the world, served in leadership roles for professional societies and not-for-profit entities, and received numerous awards for leadership and service. Dr. Levine is also an adjunct professor at Rutgers Medical School. Bekanntmachung • Jan 16
compass Pathways plc Announces the Termination of Matthew Allen Owens as A Director COMPASS Pathways plc announced the termination of Matthew Allen Owens as a director on 31 December 2024. Bekanntmachung • Jan 10
COMPASS Pathways plc has completed a Follow-on Equity Offering in the amount of $149.767589 million. COMPASS Pathways plc has completed a Follow-on Equity Offering in the amount of $149.767589 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 24,014,728
Price\Range: $4.275
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 11,044,720
Price\Range: $4.2649 Bekanntmachung • Oct 31
COMPASS Pathways plc Announces Business Updates COMPASS Pathways plc announced business updates. COMP360 psilocybin treatment in TRD: The phase 3 clinical program of COMP360 psilocybin treatment in TRD is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Top-line pivotal COMP005 trial data is expected in the second quarter 2025. In addition, as a result of the increased regulatory scrutiny on functional unblinding, the company has decided to shift the data release for COMP006 until after the 26-week time point and the completion of the blinded portion has been reached for all patients to protect against the risk of unblinding. With this change, Compass now expects data for COMP006 in the second half of 2026. As a result of changing timelines for the phase 3 trials, the company will be reducing its workforce by approximately 30%, including eliminating some senior management positions, to further focus the organization and its capital resources on successfully delivering the COMP360 program. The company’s non-COMP360 preclinical efforts will be stopped and the company is exploring a potential externalization for its digital health tools. Bekanntmachung • Oct 24
COMPASS Pathways plc to Report Q3, 2024 Results on Oct 31, 2024 COMPASS Pathways plc announced that they will report Q3, 2024 results on Oct 31, 2024 Bekanntmachung • Aug 01
COMPASS Pathways plc Appoints Gino Santini as Chairman Effective September 3, 2024 COMPASS Pathways plc announced that Gino Santini will join the Board of Directors as Chairman effective September 3, 2024. Mr. Santini brings more than a decade of board leadership and governance expertise in both public and private global corporations. He currently serves as lead independent director for Collegium Pharmaceuticals and has served as an advisor and board director to US and European venture capital, pharmaceutical, and biotechnology companies since 2011. During his director tenure across more than ten boards, including prior board service at Horizon, Intercept Pharmaceuticals and AMAG Pharmaceuticals, Mr. Santini has honed his governance experience as Chairman, Lead Independent Director, and in multiple Committee chair roles. Throughout his nearly three decades at Eli Lilly and Company, he played a leading role in several M&A transactions and led US operations, corporate strategy and business development. David Norton, who has been serving as Interim Chairman of the Board, will continue to be a member of the Board. Lori Englebert joined Compass Pathways as Chief Commercial Officer in July. In her prior role at Axsome Therapeutics, she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy. Compass previously announced the appointment of Michael Gold as Chief Research and Development Officer. Dr. Gold took up his post in the second quarter. Bekanntmachung • Jun 26
Compass Pathways plc Appoints Lori Englebert as Chief Commercial Officer, Effective July 8, 2024 Compass Pathways plc announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company’s New York City office. Lori brings multifaceted experience in global pharmaceuticals and joins from Axsome Therapeutics, where she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy. She played an integral role in bringing the company from clinical-stage to commercial-stage and was responsible for formulating commercial launch strategy and scaling the commercial organization. Over her career, Lori has launched multiple CNS-focused assets, at Axsome and at Amgen, where she spent nearly a decade in several global brand roles, including neuroscience and oncology/hematology, as well as roles in commercial strategy and operations, corporate strategy and business development. Lori’s appointment follows that of Teri Loxam as Chief Financial Officer in March 2024 and Dr. Michael Gold as Chief Research & Development Officer in May 2024. All three executive team members bring decades of successful strategic leadership and highly relevant experience in drug development. Bekanntmachung • May 09
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder Compass Pathways plc reported top-line results from an open-label phase 2 study evaluating the safety and tolerability of investigational COMP360 psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The study met its primary safety endpoint and available secondary efficacy endpoints. Study observations included meaningful and sustained symptom improvement from baseline in mean CAPS-5 total score, a measure of disease severity, and in Sheehan Disability Scale (SDS) score, a measure of functional impairment in daily life. Administration of COMP360 was well-tolerated, with a safety profile consistent with previous studies. The key findings include: Administration was well tolerated, with no serious adverse events observed. There were no treatment-emergent serious adverse events. Treatment-emergent adverse events included headache (n=11 or 50.0%), nausea (n=8 or 36.4%), crying (n=6 or 27.3%), and fatigue (n=6 or 27.,3%). There were two adverse events of suicidal ideation that resolved during the study. The first was a moderate and transient event which resolved on administration day in a patient who went on to be a responder, and it was deemed to be related to study drug. The second event was mild and occurred at week 7 in a non-responder, resolved during the study, and was deemed to be possibly related to study drug. Both participants had previous history of suicidality as measured by the Columbia-Suicide Severity Rating Scale.urable improvement in symptoms from baseline observed following a single administration. Improvements in mean CAPS- 5 total score from a baseline of 47.5 was observed (29.9 point reduction at week 4 and 29.5 point reduction at week 12). Improvement over time in Sheehan Disability Scale ("SDS") measure of functional impairment over 12 weeks. From a mean SDS total score of 22.7 at baseline, there was a 11.7 point reduction at week 4 and a 14.4 point reduction at week 12. High and sustained rates of response and remission relative to baseline, with early onset of symptom improvement. Response, as defined by patients experiencing a 15-point improvement on CAPS-5 score, was 81.8% at week 4 and 77.3% at week 12. Remission, as defined by CAPS-5 total score of 20, was 63.6% at week 4 and 54.5% at week 12. No patients withdrew from the study and no patients returned to antidepressant medication treatment during the trial. The open-label, multi-center, phase 2 safety study evaluated investigational COMP360 psilocbin treatment in 22 patients with PTSD resulting from trauma in adulthood. Participants received a single 25mg dose along with psychological support. Geological support was provided by a licensed medical professional to ensure patient safety, which consisted of preparing participants for the treatment session, observing and being present with patients during the session and supporting them after the session. Primary endpoint was safety at week 12; available secondary endpoints were change in CAPS-5 from baseline and change in SDS total score from baseline. The mean baseline severity of symptoms was a baseline of 47.5 (minimum of 25; maximum of 64) CAPS-5 total score. The mean baseline severity of symptom severity of symptoms was a baseline the baseline of 47.5 (minimum of 25; maximum of 64). The CAPS-5 total score), which is considered severe. The CAPS-5 assessment involves a structured interview that provides a PTSD diagnosis and measures symptom severity. The average age of participants at the time of screening was 39 and patients diagnosed with complex PTSD were excluded from study eligibility. The study was conducted at The Institute of Psychiatry, Psychology and Neuroscience at King's College London, Icahn School of Medicine at Mount Sinai in New York and Sunstone Therapies in Rockville, Maryland. Bekanntmachung • Apr 09
COMPASS Pathways plc, Annual General Meeting, May 09, 2024 COMPASS Pathways plc, Annual General Meeting, May 09, 2024, at 10:00 US Eastern Standard Time. Location: the offices of Goodwin Procter LLP, Sancroft, Paternoster Square London United Kingdom Agenda: To re-elect as a director David Norton, who retires by rotation in accordance with the Company’s Articles of Association; to re-elect as a director Wayne J. Riley, who retires by rotation in accordance with the Company’s Articles of Association; to re-elect as a director Daphne Karydas, who retires by rotation in accordance with the Company’s Articles of Association; to re-appoint PricewaterhouseCoopers LLP, an English registered limited liability partnership, as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders; and to consider other matters. Bekanntmachung • Mar 01
COMPASS Pathways plc to Report Q4, 2023 Results on Feb 29, 2024 COMPASS Pathways plc announced that they will report Q4, 2023 results on Feb 29, 2024 
